Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer

Komori, Tsuyoshi; Narabayashi, Isamu; Aratani, Taizo; Sueyoshi, Kozo; Tatsu, Y; Adachi, I; Shimizu, Tadafumi

doi:10.1016/s0169-5002(00)80867-3

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But there was no correlation between WR of 99m Tc-MIBI and duration of survival. Komori et al [7] previously found significantly longer survival only in patients with a higher retention index. In this study, we found that patients with ER and DR values above 3 had a significantly better prognosis than those with values below 3 (P<0.009 for ER and P<0.04 for DR).…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis

et al. 2002

View full text Add to dashboard Cite

Higher technetium-99m methoxyisobutylisonitrile (MIBI) uptake in non-small cell lung cancer (NSCLC) has been reported to be associated with a positive response to chemotherapy. It has previously been found that in tumour cells, P-glycoprotein (Pgp) expression is of importance for tracer uptake. However, some studies have indicated that Pgp expression does not play an important role in (99m)Tc-MIBI uptake in NSCLC; indeed, a negative correlation between (99m)Tc-MIBI uptake and Pgp expression has been reported. Against the background of conflicting results, our aim was to evaluate the relationship between (99m)Tc-MIBI uptake, prognosis and Pgp expression in NSCLC. A total of 37 patients with NSCLC underwent (99m)Tc-MIBI single-photon emission tomography (SPET) before chemotherapy. In 19 patients both Pgp and p53 expression, and in two patients only p53 expression (due to the limited biopsy material), were measured with immunohistochemical staining. (99m)Tc-MIBI uptake was significantly higher in responders than in non-responders: 3.09+/-1.14 vs 2.24+/-0.88 ( P<0.03) and 3.09+/-1.08 vs 2.37+/-1.06 ( P<0.05) for the early ratio (ER) and the delayed ratio (DR), respectively. The wash-out rate (WR) of responders was not significantly different from that of non-responders. We found no significant differences in ER, DR and WR among the groups positive or negative for Pgp and p53 status. There was a significant positive correlation between the survival rate and both ER and DR: r=0.49 ( P=0.003) and r=0.40 ( P=0.018), respectively. Patients with ER and DR values above 3 showed significantly longer survival than those with values below 3: 14.7+/-8.5 months vs 7.3+/-5.1 months ( P<0.009) and 13.2+/-8.4 months vs 7.4+/-5.3 months ( P<0.04) for ER and DR, respectively. However, interestingly, and in contrast to expectations, patients with a Pgp score of +2 showed significantly longer survival (12.9+/-6.7 months) than those with Pgp scores of +1 (4.4+/-3.0 months) or - (negative) (3.8+/-2.2 months) ( P<0.009 and P<0.02, respectively). Our results suggest that in NSCLC, patients with higher (99m)Tc-MIBI uptake tend to show a positive response to chemotherapy, and patients with ER and DR values above 3 have a significantly better prognosis. We also found that Pgp expression seems to play only a minor role in (99m)Tc-MIBI uptake. Our finding that patients with ER and DR values above 3 have a better prognosis needs to be confirmed in larger series of patients.

show abstract

Section: Discussionmentioning

confidence: 91%

“…Consequently, 99m Tc-MIBI is adequate for tumour imaging [3,4]. In lung cancer, higher 99m Tc-MIBI uptake in nonsmall cell lung cancer (NSCLC) has been reported to be associated with a positive response to chemotherapy [5,6,7,8,9].…”

Section: Introductionmentioning

confidence: 99%

99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Investigations of MIBI uptake in tumors in other sites than the breast have been reported. Several small studies found quantitative measures of MIBI uptake in lung tumors to be predictive of survival 20–22. Breast carcinoma studies that examined MIBI localization in breast tumors compared with normal breast tissue reported its application in breast carcinoma diagnosis,23–26 assessment of response to therapy,5, 6 and identification of multidrug resistance 27–29.…”

Section: Discussionmentioning

confidence: 99%

Residual tumor uptake of [^99mTc]‐sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival

Dunnwald

Gralow

Ellis

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUND Studies utilizing serial [99mTc]‐sestamibi (MIBI) scintimammography have reported accurate prediction of tumor response in patients with locally advanced breast carcinoma (LABC) undergoing neoadjuvant chemotherapy. The pathologic response of LABC to presurgical treatment regimens is a prognostic indicator of survival. The authors tested whether MIBI uptake posttherapy predicted survival. METHODS Sixty‐two patients with LABC underwent MIBI scintimammography just before chemotherapy and 2 months after treatment initiation. An additional MIBI scan was performed if treatment lasted > 3 months. The affected breast was imaged within 10 minutes after injection to reflect early uptake, which the authors have shown to be related to tumor blood flow. MIBI uptake was quantified using the lesion‐to‐normal breast (L:N) ratio. Most patients (93%) received weekly dose‐intensive doxorubicin‐based treatment. Disease‐free survival (DFS) and overall survival (OS) were compared with posttherapy primary MIBI uptake and with other established prognostic factors for neoadjuvantly treated LABC, namely, primary tumor pathologic response and posttherapy axillary lymph node status. RESULTS Patients with high uptake on the last observed MIBI scan (i.e., the L:N ratio was greater than the median value) had poorer DFS and OS (P < 0.01 and P = 0.01, respectively). Residual MIBI uptake retained independent prognostic significance in preliminary multivariate analysis that included other established prognostic markers. CONCLUSIONS High primary breast tumor MIBI uptake after neoadjuvant chemotherapy predicted poor survival, suggesting serial MIBI imaging may provide a useful quantitative surrogate end point for neoadjuvant chemotherapy trials. Given the association between MIBI uptake and tumor blood flow, this prognostic capability may be related to retained tumor vascularity after treatment. Cancer 2005. © 2005 American Cancer Society.

show abstract

Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer

Cited by 2 publications

References 0 publications

99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis

99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis

Residual tumor uptake of [^99mTc]‐sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival

Contact Info

Product

Resources

About

Technetium-99m MIBI single photon emission computed tomography as an indicator of prognosis for patients with lung cancer

Cited by 2 publications

References 0 publications

99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis

99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis

Residual tumor uptake of [99mTc]‐sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival

Contact Info

Product

Resources

About

Residual tumor uptake of [^99mTc]‐sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival